M.Sc. program in Zoology, Faculty of Science, Chulalongkorn University, Bangkok, 10330, Thailand.
Department of Biology, Faculty of Science, Chulalongkorn University, Bangkok, 10330, Thailand.
Parasit Vectors. 2021 Nov 8;14(1):571. doi: 10.1186/s13071-021-05078-6.
Vaccines against the sexual stages of the malarial parasite Plasmodium falciparum are indispensable for controlling malaria and abrogating the spread of drug-resistant parasites. Pfs25, a surface antigen of the sexual stage of P. falciparum, is a leading candidate for transmission-blocking vaccine development. While clinical trials have reported that Pfs25-based vaccines are safe and effective in inducing transmission-blocking antibodies, the extent of the genetic diversity of Pfs25 in malaria endemic populations has rarely been studied. Thus, this study aimed to investigate the global diversity of Pfs25 in P. falciparum populations.
A database of 307 Pfs25 sequences of P. falciparum was established. Population genetic analyses were performed to evaluate haplotype and nucleotide diversity, analyze haplotypic distribution patterns of Pfs25 in different geographical populations, and construct a haplotype network. Neutrality tests were conducted to determine evidence of natural selection. Homology models of the Pfs25 haplotypes were constructed, subjected to molecular dynamics (MD), and analyzed in terms of flexibility and percentages of secondary structures.
The Pfs25 gene of P. falciparum was found to have 11 unique haplotypes. Of these, haplotype 1 (H1) and H2, the major haplotypes, represented 70% and 22% of the population, respectively, and were dominant in Asia, whereas only H1 was dominant in Africa, Central America, and South America. Other haplotypes were rare and region-specific, resulting in unique distribution patterns in different geographical populations. The diversity in Pfs25 originated from ten single-nucleotide polymorphism (SNP) loci located in the epidermal growth factor (EGF)-like domains and anchor domain. Of these, an SNP at position 392 (GGA/GCA), resulting in amino acid substitution 131 (Gly/Ala), defined the two major haplotypes. The MD results showed that the structures of H1 and H2 variants were relatively similar. Limited polymorphism in Pfs25 could likely be due to negative selection.
The study successfully established a Pfs25 sequence database that can become an essential tool for monitoring vaccine efficacy, designing assays for detecting malaria carriers, and conducting epidemiological studies of P. falciparum. The discovery of the two major haplotypes, H1 and H2, and their conserved structures suggests that the current Pfs25-based vaccines could be used globally for malaria control.
针对疟原虫性疟疾病原体性疟原虫的性阶段的疫苗对于控制疟疾和消除耐药寄生虫的传播是不可或缺的。PfS25,疟原虫性阶段的表面抗原,是一种主要的候选疫苗开发的阻断传播疫苗。虽然临床试验报告表明 PfS25 为基础的疫苗是安全有效的诱导传播阻断抗体,PfS25 的遗传多样性的程度在疟疾流行地区的人群很少有研究。因此,本研究旨在调查 PfS25 在疟原虫人群中的全球多样性。
建立了一个 307 个 PfS25 序列的疟原虫数据库。进行群体遗传分析,以评估单倍型和核苷酸多样性,分析 PfS25 在不同地理种群中的单倍型分布模式,并构建单倍型网络。进行中性检验,以确定自然选择的证据。PfS25 单倍型的同源模型被构建,并进行分子动力学(MD)分析,从灵活性和二级结构的百分比方面进行分析。
PfS25 基因的疟原虫被发现有 11 个独特的单倍型。其中,单倍型 1(H1)和 H2,主要单倍型,分别代表 70%和 22%的人口,并且在亚洲占主导地位,而只有 H1 在非洲,中美洲和南美洲占主导地位。其他单倍型是罕见的和特定于区域的,导致在不同地理种群中的独特分布模式。PfS25 的多样性来源于位于表皮生长因子(EGF)样结构域和锚定结构域的十个单核苷酸多态性(SNP)位点。其中,位于 392 位(GGA/GCA)的 SNP 导致 131 位氨基酸(Gly/Ala)取代,定义了两个主要的单倍型。MD 结果表明,H1 和 H2 变体的结构相对相似。PfS25 中的有限多态性可能是由于负选择。
本研究成功建立了一个 PfS25 序列数据库,可成为监测疫苗效力、设计检测疟疾病例的检测方法以及进行 PfS25 流行区流行病学研究的重要工具。两个主要单倍型 H1 和 H2 的发现及其保守结构表明,目前基于 PfS25 的疫苗可在全球范围内用于疟疾控制。